Skip to main content
SpringerLink
Log in

Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase that downregulates fibrinolysis and might play some roles in the pathogenesis of disseminated intravascular coagulation (DIC). We prospectively examined the plasma TAFI antigen levels in patients highly suspected to be suffering from DIC. Patients were subdivided into overt DIC and non-DIC groups according to a DIC scoring system. The Sepsis-related Organ Failure Assessment (SOFA) scores were concurrently calculated on patients with sepsis. Overall, there were 23 non-DIC patients and 20 patients with overt DIC. Their baseline characteristics were similar, but patients with overt DIC had much more aberrant coagulation tests and higher lactate dehydrogenase levels. However, there was no significant difference between overt DIC and non-DIC patients regarding their TAFI antigen levels [median/interquartile range (IQR) 74.41/13.98 and 75.29/15.16, respectively, p=0.543]. On regression analysis, TAFI antigen levels were not correlated with either C-reactive protein levels or various coagulation test results. In patients with sepsis (n=31), TAFI levels among three risk groups stratified by low (≦5), intermediate (6–10), and high (≧11) SOFA scores were not statistically disparate (median/IQR 65.24/15.14, 74.63/13.79, and 75.29/21.51, respectively, p=0.684), either. Our result indicated that plasma TAFI antigen levels did not vary significantly between patients with or without DIC. Further, they did not possess any correlation with the severity of organ injury in patients with sepsis. The role of TAFI antigen in the pathogenesis of DIC needs further elucidation by future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bouma BN, Marx PF, Mosnier LO, Meijers JC (2001) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101:329–354

    Article  CAS  PubMed  Google Scholar 

  2. Hendriks D, Scharpe S, van Sande M, Lommaert MP (1989) Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 27:277–285

    CAS  PubMed  Google Scholar 

  3. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem 271:16603–16608

    Article  CAS  PubMed  Google Scholar 

  4. Fleury V, Angles-Cano E (1991) Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 30:7630–7638

    Article  CAS  PubMed  Google Scholar 

  5. Wang W, Boffa MB, Bajzar L et al (1998) A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273:27176–27181

    Article  CAS  PubMed  Google Scholar 

  6. Sakharov DV, Plow EF, Rijken DC (1997) On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272:14477–14482

    Article  CAS  PubMed  Google Scholar 

  7. Lisman T, Leebeek FW, Mosnier LO et al (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121:131–139

    CAS  PubMed  Google Scholar 

  8. van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855–2859

    PubMed  Google Scholar 

  9. Silveira A, Schatteman K, Goossens F et al (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84:364–368

    CAS  PubMed  Google Scholar 

  10. Montaner J, Ribo M, Monasterio J et al (2003)Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34:1038–1040

    Article  CAS  PubMed  Google Scholar 

  11. Klement P, Liao P, Bajzar L (1999) A novel approach to arterial thrombolysis. Blood 94:2735–2743

    CAS  PubMed  Google Scholar 

  12. Sato T, Miwa T, Akatsu H et al (2000) Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 165:1053–1058

    CAS  PubMed  Google Scholar 

  13. Kato T, Akatsu H, Sato T et al (2000) Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Microbiol Immunol 44:719–728

    CAS  PubMed  Google Scholar 

  14. Taylor FB Jr, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330

    CAS  PubMed  Google Scholar 

  15. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710

    CAS  PubMed  Google Scholar 

  16. Wada H, Sakuragawa N, Mori Y et al (1999) Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 60:273–278

    Article  CAS  PubMed  Google Scholar 

  17. Watanabe R, Wada H, Watanabe Y et al (2001) Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104:1–6

    Article  CAS  PubMed  Google Scholar 

  18. Levi M, de Jonge E, van der Poll T, ten Cate H (1999) Disseminated intravascular coagulation. Thromb Haemost 82:695–705

    CAS  PubMed  Google Scholar 

  19. Hambleton J, Leung LL, Levi M (2002) Coagulation: consultative hemostasis. Hematology (Am Soc Hematol Educ Program) 335–352

  20. So AK, Varisco PA, Kemkes-Matthes B et al (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1:2510–2515

    Article  CAS  PubMed  Google Scholar 

  21. Donmez A, Aksu K, Celik HA et al (2005) Thrombin activatable fibrinolysis inhibitor in Behcet’s disease. Thromb Res 115:287–292

    Article  CAS  PubMed  Google Scholar 

  22. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN (1998) Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80:829–835

    CAS  PubMed  Google Scholar 

  23. Meijers JC, Oudijk EJ, Mosnier LO et al (2000) Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 108:518–523

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the research grant VGH92-033 from Taipei Veterans General Hospital. The experiments performed in our research work comply with the current laws of our country.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Chih-Cheng Chen, Jyh-Pyng Gau, Yuan-Bin Yu, Jie-Yu You, Su-Chung Lee, Hui-Chi Hsu, Wing-Keung Chau & Chao-Hung Ho

  2. Division of Hematology–Oncology, Department of Medicine, Chang Gung Memorial Hospital-Chiayi, Chiayi, Taiwan

    Chih-Cheng Chen & Kuan-Der Lee

  3. National Yang-Ming University School of Medicine, Taipei, Taiwan

    Jyh-Pyng Gau, Yuan-Bin Yu, Jie-Yu You, Hui-Chi Hsu, Wing-Keung Chau & Chao-Hung Ho

Authors
  1. Chih-Cheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kuan-Der Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jyh-Pyng Gau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan-Bin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jie-Yu You
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Su-Chung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui-Chi Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wing-Keung Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chao-Hung Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chao-Hung Ho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, CC., Lee, KD., Gau, JP. et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 84, 675–680 (2005). https://doi.org/10.1007/s00277-005-1079-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1079-4

Keywords

Search

Navigation